Headache

Anti-Calcitonin Gene-Related Peptide Antibody Therapy for Migraine

Cleveland Clinic’s Section of Headache and Facial Pain, within the Center for Neurological Restoration, is among the largest and most comprehensive centers in the world dedicated to managing and treating headache and facial pain syndrome.

Outcomes Following Treatment With CGRP Monoclonal Antibodies (N = 64)

2022

CGRP = Calcitonin Gene-Related Peptide, GAD-7 = Generalized Anxiety Disorder Questionnaire, HIT-6 = Headache Impact Test, PHQ-9 = Patient Health Questionnaire, PROMIS = Patient Reported Outcome Measurement Information System.

Treatments targeting calcitonin gene-related peptide (CGRP) were approved by the FDA in 2018 and remain one of the most innovative treatments for patients with migraine. Cleveland Clinic's Headache Center has been at the forefront in prescribing these treatments and evaluating outcomes. In 2022, 64 headache patients completed at least 1 follow-up questionnaire following initiation of CGRP treatment in 2021 or 2022. Ninety-six percent of patients had improved or stable headache impact scores.¹ PROMIS global health,² depression,³ and anxiety⁴ were stable or improved in 78% of patients or more.

References
  1. Coeytaux RR, Kaufman JS, Chao R, Mann JD, Devellis RF. Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact Test. J Clin Epidemiol. 2006 Apr;59(4):374-380.
  2. Hays RD, Bjorner JB, Revicki DA, Spritzer KL, Cella D. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res. 2009 Sep;18(7):873-880.
  3. Löwe B, Unützer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression treatment outcomes with the Patient Health Questionnaire-9. Med Care. 2004 Dec;42(12):1194-1201.
  4. Toussaint A, Hüsing P, Gumz A, Wingenfeld K, Harter M, Löwe B. Sensitivity to change and minimal clinically important difference of the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7). J Affect Disord. 2020 Mar 15;265:395-401.